The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase Ib dose escalation trial of SAR650984 (Anti-CD-38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma.
Thomas G. Martin
No relevant relationships to disclose
Karl Hsu
Employment or Leadership Position - Sanofi
Eric Charpentier
Employment or Leadership Position - Sanofi
Ravi Vij
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Lilly; Onyx
Honoraria - Celgene; Millennium; Onyx
Research Funding - Celgene; Onyx
Rachid C. Baz
Research Funding - Bristol-Myers Squibb; Celgene; Karyopharm Therapeutics; Millennium; Novartis; Sanofi
Don M. Benson
No relevant relationships to disclose
Nikoletta Lendvai
No relevant relationships to disclose